The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
van Schaik, Ron H N
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. [electronic resource] - Pharmacogenomics Aug 2011 - 1137-46 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1744-8042
10.2217/pgs.11.54 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal--therapeutic use
Aryl Hydrocarbon Hydroxylases--genetics
Breast Neoplasms--drug therapy
Combined Modality Therapy
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6--genetics
DNA, Neoplasm--genetics
Data Interpretation, Statistical
Female
Follow-Up Studies
Genotype
Humans
Lymphatic Metastasis--pathology
Menopause
Middle Aged
Pharmacogenetics
Predictive Value of Tests
Prognosis
Receptors, Progesterone--metabolism
Retrospective Studies
Survival Analysis
Tamoxifen--therapeutic use
Treatment Outcome
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. [electronic resource] - Pharmacogenomics Aug 2011 - 1137-46 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1744-8042
10.2217/pgs.11.54 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal--therapeutic use
Aryl Hydrocarbon Hydroxylases--genetics
Breast Neoplasms--drug therapy
Combined Modality Therapy
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6--genetics
DNA, Neoplasm--genetics
Data Interpretation, Statistical
Female
Follow-Up Studies
Genotype
Humans
Lymphatic Metastasis--pathology
Menopause
Middle Aged
Pharmacogenetics
Predictive Value of Tests
Prognosis
Receptors, Progesterone--metabolism
Retrospective Studies
Survival Analysis
Tamoxifen--therapeutic use
Treatment Outcome